U.S. Markets close in 6 hrs 17 mins

Zacks.com featured highlights: GlycoMimetics, Lion Biotechnologies, AMN Healthcare Services, Gibraltar Industries and Coherent

Zacks Equity Research

For Immediate Release

Chicago, IL – August 05, 2016 - Stocks in this week’s article include: GlycoMimetics Inc. (GLYC), Lion Biotechnologies Inc. (LBIO), AMN Healthcare Services Inc. (AHS), Gibraltar Industries, Inc. (ROCK) and Coherent Inc. ( COHR).

Screen of the Week of Zacks Investment Research:

Stocks with Recent Price Strength for Explosive Returns

An investor always seeks a win-win strategy, but it is easier said than done. And when the market is as volatile as it is now, things become difficult for even an ardent investor.

One could take resort to commonly used techniques to find beaten down stocks that have the potential to recover faster than others. But this also bears the risk of disappointment. Particularly, one could be stuck in the value trap if the hidden weaknesses in a selected stock is not identified.

So, wouldn’t it be a safer strategy to look for stocks that are winners currently and have the potential to gain further?

Here’s how to execute it:

One should primarily look for stocks that have recently been witnessing price increase. Actually, stocks seeing price strength recently have a high chance of carrying the momentum forward.

If a stock is continuously moving higher, there must be a good reason for the rise or else it probably would have fallen like the losers. So, looking at those stocks that have already won the game and are capable of beating the benchmark that they have already set sounds rational.

However, recent price strength alone cannot create magic, so you need to set other relevant parameters to create a successful investment strategy.

Here’s how you should create the screen to shortlist the current as well as the potential winners.

Screening Parameters:

Percentage Change in Price (4 Weeks) greater than zero: This criterion shows that the stock moved higher in the last four weeks.

Percentage Change Price (12 Weeks) greater than 10: This indicates that the stock saw momentum over the last three months. This lowers the risk of choosing stocks that may have drawn attention due to the overwhelming performance of the overall market in a very short period.

Zacks Rank 1: No matter whether the market conditions are good or bad, stocks with a Zacks Rank #1 (Strong Buy) have a proven history of outperformance.

Average Broker Rating 1: This indicates that brokers are also highly hopeful about the stock’s future performance.

Current Price greater than 5: The stocks must all be trading at a minimum of $5 or higher.

Current Price/52-Week High-Low Range more than 85%: This criterion filters stocks that are trading near their respective 52-week highs. It indicates that these are strong enough in terms of price.

Here are seven of the 10 stocks that made it through this screen:

GlycoMimetics Inc. (GLYC) is a biotechnology company. The company focuses on the discovery and development of novel glycomimetic drugs to address diseases in which carbohydrate biology plays a key role. The company beat the Zacks Consensus Estimate thrice in the preceding four quarters, with an average positive surprise of 55.9%.

Lion Biotechnologies Inc. (LBIO) develops autologous cell therapies for the treatment of cancer. The company beat the Zacks Consensus Estimate thrice in the preceding four quarters, with an average positive surprise of 19.2%.

AMN Healthcare Services Inc. (AHS) is a travel healthcare staffing company. It recruits and places nurses, physicians, and other healthcare professionals in travel or permanent assignments in acute-care facilities, physician practice groups and other healthcare facilities. The company surpassed the Zacks Consensus Estimate in each of the preceding four quarters, with an average positive surprise of 23.6%.

Gibraltar Industries, Inc. (ROCK) is a leading manufacturer, processor, and distributor of metals and other engineered materials for the building products, vehicular, and other industrial markets. The company surpassed the Zacks Consensus Estimate in each of the preceding four quarters, with an average positive surprise of 74.5%.

Coherent Inc. (COHR) designs, manufactures, and supplies electro-optical systems and medical instruments utilizing laser, precision optic and microelectronic technologies. The company surpassed the Zacks Consensus Estimate in each of the preceding four quarters, with an average positive surprise of 19.8%.

Get the rest of the stocks on the list and start putting this and other ideas to the test. It can all be done with the Research Wizard stock picking and backtesting software.

The Research Wizard is a great place to begin. It's easy to use. Everything is in plain language. And it's very intuitive. Start your Research Wizard trial today. And the next time you read an economic report, open up the Research Wizard, plug your finds in, and see what gems come out.

Click here to sign up for a free trial to the Research Wizard today.

Disclosure: Officers, directors and/or employees of Zacks Investment Research may own or have sold short securities and/or hold long and/or short positions in options that are mentioned in this material. An affiliated investment advisory firm may own or have sold short securities and/or hold long and/or short positions in options that are mentioned in this material.

Disclosure: Performance information for Zacks’ portfolios and strategies are available at: https://www.zacks.com/performance .

Zacks Restaurant Recommendations: In addition to dining at these special places, you can feast on their stock shares. A Zacks Special Report spotlights 5 recent IPOs to watch plus 2 stocks that offer immediate promise in a booming sector. Download it free »

Sign up now for your free trial today and start picking better stocks immediately. And with the backtesting feature, you can test your ideas to see how you can improve your trading in both up markets and down markets. Don’t wait for the market to get better before you decide to do better. Start learning how to be a better trader today: https://at.zacks.com/?id=111
 

Disclosure: Officers, directors and/or employees of Zacks Investment Research may own or have sold short securities and/or hold long and/or short positions in options that are mentioned in this material. An affiliated investment advisory firm may own or have sold short securities and/or hold long and/or short positions in options that are mentioned in this material.


About Screen of the Week

Zacks.com created the first and best screening system on the web earning the distinction as the "#1 site for screening stocks" by Money Magazine. But powerful screening tools is just the start. That is why Zacks created the Screen of the Week to highlight profitable stock picking strategies that investors can actively use. Each week, Zacks Profit from the Pros free email newsletter shares a new screening strategy. Learn more about it here https://at.zacks.com/?id=112

About Zacks

Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978. The later formation of the Zacks Rank, a proprietary stock picking system; continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Click here for your free subscription to Profit from the Pros.

Follow us on Twitter: https://twitter.com/zacksresearch

Join us on Facebook: https://www.facebook.com/ZacksInvestmentResearch

Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.


Contact: Jim Giaquinto
Company: Zacks.com
Phone: 312-265-9268
Email: pr@zacks.com

Visit: www.Zacks.com

Zacks.com provides investment resources and informs you of these resources, which you may choose to use in making your own investment decisions. Zacks is providing information on this resource to you subject to the Zacks "Terms and Conditions of Service" disclaimer. www.zacks.com/disclaimer .

Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
GLYCOMIMETICS (GLYC): Free Stock Analysis Report
 
LION BIOTECH (LBIO): Free Stock Analysis Report
 
AMN HLTHCR SVCS (AHS): Free Stock Analysis Report
 
GIBRALTAR INDUS (ROCK): Free Stock Analysis Report
 
COHERENT INC (COHR): Free Stock Analysis Report
 
To read this article on Zacks.com click here.